arGEN-X BV has granted a worldwide exclusive license to RuiYi to develop and commercialize ARGX-109, a novel anti-IL-6 monoclonal antibody discovered and developed by arGEN-X. arGEN-X is backed by OrbiMed Advisors, Seventure Partners, Forbion Capital Partners, Credit Agricole Private Equity, LSP, BioGeneration Ventures, the Erasmus Biomedical Fund, Thuja Capital and VIB.
You are browsing the archive for Forbion Capital Partners - peHUB.
Philip Astley-Sparke has joined Forbion Capital Partners as a venture partner based in Boston. He had been BioVex’s president and CEO since 2005. Once Amgen acquired BioVex in March 2011, Astley-Sparke served as VP and GM of Amgen until the following December. PRESS RELEASE Forbion Capital Partners today announced Philip Astley-Sparke, the former President and CEO [...]
Promedior, a clinical stage biotechnology company developing biologic therapeutics for the treatment of fibrosis, has appointed Suzanne L. Bruhn as president and chief executive officer. In March, the company announced the closing of a Series D financing round led by Fibrotec Ventures with participation from all of Promedior’s existing venture investors, including Morgenthaler Ventures, HealthCare [...]
Promedior, a clinical stage biotechnology company has raised $21.5M in a first closing of a Series D financing round. The financing was led by a new investor, Fibrotec Ventures with participation from all of Promedior’s existing venture investors, including Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, Forbion Capital Partners and Easton Capital Investment Group. This [...]
Malvern, Penn.-based Promedior Inc., a clinical stage biotechnology company developing therapeutics for fibroproliferative diseases, has held a $21.5 million first closing of its Series D round. New investor Fibrotec Ventures led the round, which included existing shareholders Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, Forbion Capital Partners and Easton Capital Investment Group. This new round [...]
arGEN-X, a biopharmaceutical company developing human monoclonal antibodies, has raised 27.5 million euro ($37 million) in Series B financing. OrbiMed Advisors and Seventure Partners co-led the round, which included participation from existing shareholders Forbion Capital Partners, Credit Agricole Private Equity, LSP, BioGeneration Ventures, the Erasmus Biomedical Fund, Thuja Capital and VIB. Mike Sheffery of OrbiMed will join the company’s board.
CircuLite, a developer of a surgically implanted blood pump for long-term use in heart failure patients, has raised $30 million for its oversubscribed Series D financing round. The round was led by new investor, MacAndrews & Forbes Holdings, and Netherlands-based Forbion Capital Partners, a founding VC of CircuLite and the largest investor in the company. [...]
Oxyrane UK Ltd., a biopharmaceutical company based in The Netherlands, has closed on $26.5 million in a equity round of funding. Investors include Forbion Capital Partners, Morningside Groups and New Science Ventures. Sander Slootweg of Forbion and Gerald Chan of Morningside Group have joined the company’s board. Oxyrane is developing enzyme replacement therapies to treat rare inheritied diseases.
AM-Pharma NV, a Dutch developer of Alkaline Phosphatase for treatment of severe inflammatory diseases, has closed on 29.2 million euro ($39.8 million) in a Series D financing round led by Ysios Capital Partners. Kurma Life Science Partners co-led the round, which included participation from the venture arms of two global Healthcare companies, Abbott and Shire. Venture funds BB Biotech Ventures, Idinvest Partners, Forbion Capital Partners and Inventages Venture Capital also joined in the round.
Forbion Capital Partners has led an 18 million euro ($25.3 million) Series A round for Belgium-based Amakem NV. Crédit Agricole Private Equity, Vesalius BioCapital, as well as the existing investors LRM, PMV and Life Sciences Research Partners also contributed to the round. Amakem will use the money to expand its ophthalmology drug development portfolio, the company said.